FDA Brief

Warning letters Biologics

FDA warning letter to

Re-Gen Active Lab, Inc.

Issued May 27, 2022Posted Jun 28, 2022Office of Biological Products Operations – Division 2

Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps). We haven't summarized this letter yet. Read it on fda.gov.